Infinity Announces the Date of Its Full Year 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., March 7, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, March 14, 2019, at 8:00 a.m. ET to review its full year 2018 financial results and provide an update on the company.
A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. To participate in the conference call, please dial 1-877-316-5293 (domestic) and 1-631-291-4526 (international) five minutes prior to start time. The conference ID number is 3569646. An archived version of the webcast will be available on Infinity's website for 30 days.
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1/1b study in approximately 225 patients with advanced solid tumors is ongoing and Infinity intends to initiate MARIO-275, a combination study of IPI-549 with Opdivo® in I/O naïve urothelial cancer (UC) patients, as well as initiate the first IPI-549 combination study in front-line advanced cancer patients, in 2019. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Stephanie Ascher, Stern Investor Relations, Inc.
212-362-1200 or Stephanie@sternir.com
SOURCE Infinity Pharmaceuticals, Inc.